Needham & Company LLC reissued their buy rating on shares of I-Mab (NASDAQ:IMAB - Free Report) in a report issued on Friday,Benzinga reports. Needham & Company LLC currently has a $4.00 target price on the stock.
Separately, Brookline Capital Management upgraded shares of I-Mab to a "strong-buy" rating in a report on Thursday, February 27th.
Read Our Latest Stock Analysis on I-Mab
I-Mab Stock Down 2.2 %
Shares of IMAB traded down $0.02 during midday trading on Friday, reaching $0.67. The stock had a trading volume of 135,824 shares, compared to its average volume of 309,699. The firm's 50 day moving average price is $0.88 and its 200-day moving average price is $1.02. I-Mab has a 52 week low of $0.60 and a 52 week high of $2.00.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in IMAB. Millennium Management LLC grew its position in I-Mab by 763.1% during the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after purchasing an additional 86,424 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of I-Mab in the fourth quarter worth $119,000. BNP Paribas Financial Markets acquired a new position in I-Mab during the fourth quarter valued at $93,000. XTX Topco Ltd lifted its stake in I-Mab by 140.8% in the 3rd quarter. XTX Topco Ltd now owns 43,039 shares of the company's stock worth $53,000 after acquiring an additional 25,163 shares in the last quarter. Finally, Garden State Investment Advisory Services LLC purchased a new stake in I-Mab in the 3rd quarter worth about $179,000. 38.38% of the stock is owned by hedge funds and other institutional investors.
About I-Mab
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Read More
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
